This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?
by Harshit Gupta
DexCom stock shines with strong fourth quarter and full-year 2024 preliminary results, driven by innovation and global expansion. Explore if it's a buy or hold for your portfolio!
Reasons to Retain TNDM Stock in Your Portfolio for Now
by Zacks Equity Research
A robust diabetes market and several strategic developments raise investors' optimism for Tandem Diabetes.
Tandem Diabetes Forges New R&D Agreement With UVA: Stock to Gain?
by Zacks Equity Research
TNDM enters a multi-year research collaboration with the UVA Center for Diabetes Technology for the development of AID systems.
Inari Medical (NARI) Soars 30.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inari Medical (NARI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada
by Zacks Equity Research
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.
Tandem Diabetes Care (TNDM) Down 9.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain TNDM Stock in Your Portfolio for Now
by Zacks Equity Research
Innovations and a robust international market expansion raise investors' optimism for Tandem Diabetes.
TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket
by Zacks Equity Research
Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 16.28% and 9.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Tandem Diabetes Care, Inc. (TNDM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -21.69% in 4 Weeks, Here's Why Tandem Diabetes Care (TNDM) Looks Ripe for a Turnaround
by Zacks Equity Research
Tandem Diabetes Care (TNDM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock
by Zacks Equity Research
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.
TNDM Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.
TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU
by Zacks Equity Research
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.
Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now
by Zacks Equity Research
Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.
New Launches Support Tandem Diabetes Stock Despite Macro Concerns
by Zacks Equity Research
The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
by Zacks Equity Research
The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
by Zacks Equity Research
Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 12.96% and 7.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical (NARI) delivered earnings and revenue surprises of -156.25% and 1.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings
by Zacks Equity Research
Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
by Zacks Equity Research
In EMEA, Boston Scientific (BSX) is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies.